Stryker Acquires Inari Medical in $4.9 Billion Deal

The acquisition strengthens Stryker's vascular device portfolio, enhancing its offerings for blood clot treatments.

Stryker will acquire Inari Medical for $80 per share in an all-cash deal valued at $4.9 billion, set to close in the first quarter of 2025.
Inari specializes in devices for treating venous thromboembolism, a condition affecting up to 900,000 people annually in the U.S.
The acquisition complements Stryker's neurovascular business and expands its capabilities in endovascular procedures.
Inari's stock surged over 50% following the announcement, while Stryker's stock saw modest fluctuations.
Stryker plans to provide further financial impact details during its January 28 earnings call.